Hui Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hui Yang has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
Yue Fu
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China
8 shared publicationsKaiqun Liu
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology Visual Science, Guangzhou, China
7 shared publicationsXiaoyu Xu
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology Visual Science, Guangzhou, China
7 shared publicationsXiaoning Liu
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology Visual Science, Guangzhou, China
6 shared publicationsYurong Zhang
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology Visual Science, Guangzhou, China
6 shared publicationsSiqi Chen
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology Visual Science, Guangzhou, China
5 shared publications
Latest Publications
- Open Access
- 9 September 2026
- Published by Wiley in Advanced Science
- p. e77701
Upadacitinib Restrains the Pathogenic Fitness of CD4 + T Cells and Aberrant B Cell Programming in Optic Neuritis
Optic neuritis (ON) is a neuroinflammatory autoimmune disease harboring autoreactive lymphocytes. Effector memory CD4 + T cells (CD4 + T em ) represent a prominently expanded and pro‐inflammatory subset within this compartment, yet their pathogenic metabolic programs remain poorly defined. B cell dysfunction also contributes to ON pathogenesis. However, whether T cell‐intrinsic metabolic rewiring directly fuels this B cell dysregulation awaits elucidation. Here, through single‐cell transcriptomic profiling of peripheral blood mononuclear cells (PBMCs) from ON patients, we conceptualized a pathological circuit linking T cell metabolic reprogramming to aberrant T‐B crosstalk. In pathogenic CD4 + T em , JAK1 upregulation and enhanced STAT3 phosphorylation propagated a metabolic rewiring transcriptional program and secured T cell fitness via MCL1 induction. An inferred cholesterol export signature distinguished this subset and engaged the nuclear sensor RORA on B cells to instruct pro‐inflammatory polarization and humoral commitment. In turn, subverted B cells perpetuated exaggerated antigen presentation and cytokine secretion, cementing pathogenic CD4 + T em differentiation and sustaining a self‐amplifying inflammatory loop. Cross‐disease profiling extended this axis to allied autoimmune disorders. Selective JAK1 blockade with upadacitinib (UPA) restored immune homeostasis and attenuated experimental autoimmune encephalomyelitis (EAE), phenocopied by MCL1 inhibition. Together, these findings nominate UPA as a targeted therapy for ON and allied autoimmune disorders.
- 9 September 2026
- Published by Wiley in Advanced Science
- p. e77701
Open AccessUpadacitinib Restrains the Pathogenic Fitness of CD4 + T Cells and Aberrant B Cell Programming in Optic Neuritis
Optic neuritis (ON) is a neuroinflammatory autoimmune disease harboring autoreactive lymphocytes. Effector memory CD4 + T cells (CD4 + T em ) represent a prominently expanded and pro‐inflammatory subset within this compartment, yet their pathogenic metabolic programs remain poorly defined. B cell dysfunction also contributes to ON pathogenesis. However, whether T cell‐intrinsic metabolic rewiring directly fuels this B cell dysregulation awaits elucidation. Here, through single‐cell transcriptomic profiling of peripheral blood mononuclear cells (PBMCs) from ON patients, we conceptualized a pathological circuit linking T cell metabolic reprogramming to aberrant T‐B crosstalk. In pathogenic CD4 + T em , JAK1 upregulation and enhanced STAT3 phosphorylation propagated a metabolic rewiring transcriptional program and secured T cell fitness via MCL1 induction. An inferred cholesterol export signature distinguished this subset and engaged the nuclear sensor RORA on B cells to instruct pro‐inflammatory polarization and humoral commitment. In turn, subverted B cells perpetuated exaggerated antigen presentation and cytokine secretion, cementing pathogenic CD4 + T em differentiation and sustaining a self‐amplifying inflammatory loop. Cross‐disease profiling extended this axis to allied autoimmune disorders. Selective JAK1 blockade with upadacitinib (UPA) restored immune homeostasis and attenuated experimental autoimmune encephalomyelitis (EAE), phenocopied by MCL1 inhibition. Together, these findings nominate UPA as a targeted therapy for ON and allied autoimmune disorders.
- 15 July 2026
- Published by Springer Nature in Eye
- Vol. 40 (14) , 2298-2300
Long-term optic nerve safety of low-dose IMRT versus glucocorticoids in thyroid eye disease: an 8-year multimodal age-adjusted study
- 15 July 2026
- Published by Springer Nature in Eye
- Vol. 40 (14) , 2298-2300
Long-term optic nerve safety of low-dose IMRT versus glucocorticoids in thyroid eye disease: an 8-year multimodal age-adjusted study
- Open Access
- 5 January 2026
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Translational Vision Science & Technology
- Vol. 15 (1) , 13
Prognostic Modeling for the Failure of Intravenous Methylprednisolone and the Risk of Visual Disability in AQP4-IgG Positive NMOSD-ON
To identify factors influencing best corrected visual acuity (BCVA) prognosis in patients with AQP4-IgG+ neuromyelitis optica spectrum disorder-related optic neuritis (NMOSD-ON) after treating with high-dose intravenous methylprednisolone. A total of 161 intravenous methylprednisolone (IVMP)-treated patients were randomized into training (n = 113) and internal validation (n = 48) sets at a ratio of 7:3. Using Least Absolute Shrinkage and Selection Operator regression, 16 candidate predictors were screened to construct a logistic model to predict follow-up BCVA after six months post-ON attack. Discrimination (area under curve [AUC]), calibration, and clinical net benefit (decision curve analysis [DCA]) were assessed. The final model included seven predictors: age, AQP4-IgG titer, non-ON attack history, baseline BCVA, mean deviation, macular ganglion cell inner plexiform layer thickness, and treatment window. AUCs were 0.904 (95% confidence interval [CI], 0.850-0.959) and 0.864 (95% CI, 0.761-0.967) in training and validation sets, respectively. Calibration curves indicated high consistency, and DCA demonstrated significant net benefit at 10%-90% risk thresholds. The validated prediction model effectively stratifies IVMP-treated patients at risk of visual disability, enabling precision management. By converting heterogeneous prognostic factors into a practical prediction tool, this work empowers clinicians to deliver precision care for a blinding complication of NMOSD, directly reducing preventable visual disability.
- 5 January 2026
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Translational Vision Science & Technology
- Vol. 15 (1) , 13
Open AccessPrognostic Modeling for the Failure of Intravenous Methylprednisolone and the Risk of Visual Disability in AQP4-IgG Positive NMOSD-ON
To identify factors influencing best corrected visual acuity (BCVA) prognosis in patients with AQP4-IgG+ neuromyelitis optica spectrum disorder-related optic neuritis (NMOSD-ON) after treating with high-dose intravenous methylprednisolone. A total of 161 intravenous methylprednisolone (IVMP)-treated patients were randomized into training (n = 113) and internal validation (n = 48) sets at a ratio of 7:3. Using Least Absolute Shrinkage and Selection Operator regression, 16 candidate predictors were screened to construct a logistic model to predict follow-up BCVA after six months post-ON attack. Discrimination (area under curve [AUC]), calibration, and clinical net benefit (decision curve analysis [DCA]) were assessed. The final model included seven predictors: age, AQP4-IgG titer, non-ON attack history, baseline BCVA, mean deviation, macular ganglion cell inner plexiform layer thickness, and treatment window. AUCs were 0.904 (95% confidence interval [CI], 0.850-0.959) and 0.864 (95% CI, 0.761-0.967) in training and validation sets, respectively. Calibration curves indicated high consistency, and DCA demonstrated significant net benefit at 10%-90% risk thresholds. The validated prediction model effectively stratifies IVMP-treated patients at risk of visual disability, enabling precision management. By converting heterogeneous prognostic factors into a practical prediction tool, this work empowers clinicians to deliver precision care for a blinding complication of NMOSD, directly reducing preventable visual disability.
- Open Access
- 1 January 2026
- Published by Maximum Academic Press in Visual Neuroscience
- Vol. 43 (1)
Changes in the ganglion cell–inner plexiform layer in diabetic patients imaged by optical coherence tomography: a three-year prospective cohort study
This prospective observational cohort study aimed to identify predictive factors for the progression of ganglion cell–inner plexiform layer (GCIPL) thinning in patients with Type 2 diabetes mellitus (T2DM). In total, 2,123 consecutive patients with T2DM were included and followed up for three years. All participants underwent 3 mm × 3 mm optical coherence tomography (OCT) imaging centered on the macula. After image quality control, data from 1,500 patients (1,500 eyes) were analyzed. Longer baseline axial length (AL), higher baseline intraocular pressure, poorer baseline best corrected visual acuity (BCVA), greater baseline macular retinal thickness, greater baseline macular GCIPL thickness, and a wider glycated hemoglobin (HbA1c) fluctuation range were associated with a higher rate of decline in GCIPL (p < 0.001). In the final multivariate regression model, longer AL (β = −0.187; 95% confidence interval [CI]: −0.255 to −0.120 mm/year; p < 0.001), poorer baseline BCVA (β = −0.201; 95% CI: −0.271 to −0.130; p < 0.001), greater baseline macular retinal thickness (β = −0.126; 95% CI: −0.198 to −0.054 μm/year; p = 0.001), greater baseline macular GCIPL thickness (β = −0.305; 95% CI: −0.376 to −0.235 μm/year; p < 0.001), and more microalbuminuria (β = −0.069; 95% CI: −0.136 to −0.002 mg/ml/year; p = 0.045) were independently associated with a higher rate of GCIPL decline. These factors are major predictors of GCIPL loss in T2DM and should be considered when interpreting GCIPL measurements in clinical practice and research.
- 1 January 2026
- Published by Maximum Academic Press in Visual Neuroscience
- Vol. 43 (1)
Open AccessChanges in the ganglion cell–inner plexiform layer in diabetic patients imaged by optical coherence tomography: a three-year prospective cohort study
This prospective observational cohort study aimed to identify predictive factors for the progression of ganglion cell–inner plexiform layer (GCIPL) thinning in patients with Type 2 diabetes mellitus (T2DM). In total, 2,123 consecutive patients with T2DM were included and followed up for three years. All participants underwent 3 mm × 3 mm optical coherence tomography (OCT) imaging centered on the macula. After image quality control, data from 1,500 patients (1,500 eyes) were analyzed. Longer baseline axial length (AL), higher baseline intraocular pressure, poorer baseline best corrected visual acuity (BCVA), greater baseline macular retinal thickness, greater baseline macular GCIPL thickness, and a wider glycated hemoglobin (HbA1c) fluctuation range were associated with a higher rate of decline in GCIPL (p < 0.001). In the final multivariate regression model, longer AL (β = −0.187; 95% confidence interval [CI]: −0.255 to −0.120 mm/year; p < 0.001), poorer baseline BCVA (β = −0.201; 95% CI: −0.271 to −0.130; p < 0.001), greater baseline macular retinal thickness (β = −0.126; 95% CI: −0.198 to −0.054 μm/year; p = 0.001), greater baseline macular GCIPL thickness (β = −0.305; 95% CI: −0.376 to −0.235 μm/year; p < 0.001), and more microalbuminuria (β = −0.069; 95% CI: −0.136 to −0.002 mg/ml/year; p = 0.045) were independently associated with a higher rate of GCIPL decline. These factors are major predictors of GCIPL loss in T2DM and should be considered when interpreting GCIPL measurements in clinical practice and research.
- Open Access
- 1 January 2026
- Published by Maximum Academic Press in Visual Neuroscience
- Vol. 43 (1)
Comparison of the clinical characteristics and visual outcomes of early- and late-onset optic neuritis
This retrospective single-center study (January 2016 to January 2022) compared the clinical characteristics and visual outcomes between late-onset optic neuritis (LO-ON, onset age ≥ 50 years, n = 66) and early-onset optic neuritis (EO-ON, onset age < 50 years, n = 205) across different etiological subtypes, including neuromyelitis optica spectrum disorder-related optic neuritis (ON) (NMOSD-ON, n = 112), myelin oligodendrocyte glycoprotein antibody-associated ON (MOG-ON, n = 42), and idiopathic ON (IDON, n = 117). All participants were of Asian (Han) ethnicity, with a female-to-male ratio of 2.2:1 and a mean age of 39.9 years (range: 18.0–83.0). Overall, LO-ON accounted for 24.4% of all ON patients and had worse final outcomes than EO-ON in terms of best-corrected visual acuity (BCVA; a median difference = logarithm of the minimum angle of resolution [logMAR] of 0.20, 95% confidence interval [CI]: 0.05 to 0.30, p = 0.003) and visual field mean deviation (VF MD; median difference = −10.00 dB, 95% CI: −15.00 to −4.00, p = 0.001). LO-MOG-ON had a worse BCVA than EO-MOG-ON both at onset (median difference = 0.55 logMAR, 95% CI: 0.10–1.10, p = 0.008) and final follow-up (median difference = 0.20 logMAR, 95% CI: 0.00–0.50, p = 0.042). LO-IDON had a worse final BCVA (median difference = 0.20 logMAR, 95% CI: 0.05–0.40, p = 0.012) and VF MD (median difference = −12.00 dB, 95% CI: −18.00 to −6.00, p = 0.0004) than EO-IDON. No differences existed between LO- and EO-NMOSD-ON. Among LO-ON subtypes, severity at onset was similar. LO-MOG-ON had the best final recovery; LO-NMOSD-ON had the worst VF, the thinnest ganglion cell layer, and the highest relapse rate (75%); LO-IDON had the highest rate of brain demyelinating lesions revealed by magnetic resonance imaging (MRI) (43.3%). Structural damage of the optic nerve was similar between EO-ON and LO-ON across subtypes. LO-MOG-ON and LO-IDON had a poorer final prognosis than their early-onset counterparts.
- 1 January 2026
- Published by Maximum Academic Press in Visual Neuroscience
- Vol. 43 (1)
Open AccessComparison of the clinical characteristics and visual outcomes of early- and late-onset optic neuritis
This retrospective single-center study (January 2016 to January 2022) compared the clinical characteristics and visual outcomes between late-onset optic neuritis (LO-ON, onset age ≥ 50 years, n = 66) and early-onset optic neuritis (EO-ON, onset age < 50 years, n = 205) across different etiological subtypes, including neuromyelitis optica spectrum disorder-related optic neuritis (ON) (NMOSD-ON, n = 112), myelin oligodendrocyte glycoprotein antibody-associated ON (MOG-ON, n = 42), and idiopathic ON (IDON, n = 117). All participants were of Asian (Han) ethnicity, with a female-to-male ratio of 2.2:1 and a mean age of 39.9 years (range: 18.0–83.0). Overall, LO-ON accounted for 24.4% of all ON patients and had worse final outcomes than EO-ON in terms of best-corrected visual acuity (BCVA; a median difference = logarithm of the minimum angle of resolution [logMAR] of 0.20, 95% confidence interval [CI]: 0.05 to 0.30, p = 0.003) and visual field mean deviation (VF MD; median difference = −10.00 dB, 95% CI: −15.00 to −4.00, p = 0.001). LO-MOG-ON had a worse BCVA than EO-MOG-ON both at onset (median difference = 0.55 logMAR, 95% CI: 0.10–1.10, p = 0.008) and final follow-up (median difference = 0.20 logMAR, 95% CI: 0.00–0.50, p = 0.042). LO-IDON had a worse final BCVA (median difference = 0.20 logMAR, 95% CI: 0.05–0.40, p = 0.012) and VF MD (median difference = −12.00 dB, 95% CI: −18.00 to −6.00, p = 0.0004) than EO-IDON. No differences existed between LO- and EO-NMOSD-ON. Among LO-ON subtypes, severity at onset was similar. LO-MOG-ON had the best final recovery; LO-NMOSD-ON had the worst VF, the thinnest ganglion cell layer, and the highest relapse rate (75%); LO-IDON had the highest rate of brain demyelinating lesions revealed by magnetic resonance imaging (MRI) (43.3%). Structural damage of the optic nerve was similar between EO-ON and LO-ON across subtypes. LO-MOG-ON and LO-IDON had a poorer final prognosis than their early-onset counterparts.
- Open Access
- 23 April 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1-12
Temporal evolution and factors influencing visual function and RNFL thickness in ethambutol-associated optic neuropathy
This study aimed to investigate the temporal evolution and influencing factors of visual function and optic nerve structure in ethambutol-associated optic neuropathy (EON). In this single-center retrospective observational study, we analyzed data from 48 EON patients (26 males and 22 females) with a 12-month follow-up. Comprehensive ophthalmologic assessments, including best corrected visual acuity (BCVA), visual field (VF), optical coherence tomography (OCT), and magnetic resonance imaging (MRI), were conducted to evaluate visual function and optic nerve structure. Statistical analyses including multiple linear regression and comparative analyses (independent t-tests/Mann–Whitney U tests) were performed to identify factors influencing recovery, with effect sizes calculated using Cohen’s d. Significant improvements in best corrected visual acuity and visual field were observed between 3 and 6 months. The mean improvement in BCVA was 0.25 logMAR (from 1.28 ± 0.64 at 3 months to 0.82 ± 0.60 at 6 months, p < 0.0001, Cohen’s d = 0.74, 95% CI [0.33, 1.15]), and the mean improvement in VF mean deviation was 2.5 dB (from − 13.85 ± 9.23 dB at 3 months to − 10.33 ± 7.58 dB at 6 months, p = 0.037, Cohen’s d = 0.42, 95% CI [0.11, 6.93]), indicating a critical recovery window. Peripapillary retinal nerve fiber layer (pRNFL) thinning was most pronounced between 3 and 9 months, with the temporal quadrant showing the earliest thinning (40.21% reduction by 3 months). Macular ganglion cell-inner plexiform layer (mGCIPL) thickness showed a decreasing trend (73.20 ± 4.76 μm to 55.33 ± 4.16 μm) from 1 month post-onset. Multivariate analysis revealed that disease course was the primary factor influencing VF recovery (β = − 0.31, p = 0.001), while peripapillary retinal nerve fiber layer thinning was associated with gender, ethambutol dosage, and disease duration. Female patients exhibited slower peripapillary retinal nerve fiber layer thinning compared to males. This study identifies a critical recovery window for visual function in EON between 3 and 6 months, with peripapillary retinal nerve fiber layer thinning progressing significantly between 3 and 9 months. The temporal quadrant of the peripapillary retinal nerve fiber layer may serve as an early marker for disease progression. These findings provide valuable insights for optimizing monitoring and intervention strategies in EON patients, highlighting that early therapeutic interventions—particularly for patients showing temporal RNFL thinning or high-risk features—may maximize visual recovery potential.
- 23 April 2025
- Published by Springer Nature in European Journal of Medical Research
- Vol. 30 (1) , 1-12
Open AccessTemporal evolution and factors influencing visual function and RNFL thickness in ethambutol-associated optic neuropathy
This study aimed to investigate the temporal evolution and influencing factors of visual function and optic nerve structure in ethambutol-associated optic neuropathy (EON). In this single-center retrospective observational study, we analyzed data from 48 EON patients (26 males and 22 females) with a 12-month follow-up. Comprehensive ophthalmologic assessments, including best corrected visual acuity (BCVA), visual field (VF), optical coherence tomography (OCT), and magnetic resonance imaging (MRI), were conducted to evaluate visual function and optic nerve structure. Statistical analyses including multiple linear regression and comparative analyses (independent t-tests/Mann–Whitney U tests) were performed to identify factors influencing recovery, with effect sizes calculated using Cohen’s d. Significant improvements in best corrected visual acuity and visual field were observed between 3 and 6 months. The mean improvement in BCVA was 0.25 logMAR (from 1.28 ± 0.64 at 3 months to 0.82 ± 0.60 at 6 months, p < 0.0001, Cohen’s d = 0.74, 95% CI [0.33, 1.15]), and the mean improvement in VF mean deviation was 2.5 dB (from − 13.85 ± 9.23 dB at 3 months to − 10.33 ± 7.58 dB at 6 months, p = 0.037, Cohen’s d = 0.42, 95% CI [0.11, 6.93]), indicating a critical recovery window. Peripapillary retinal nerve fiber layer (pRNFL) thinning was most pronounced between 3 and 9 months, with the temporal quadrant showing the earliest thinning (40.21% reduction by 3 months). Macular ganglion cell-inner plexiform layer (mGCIPL) thickness showed a decreasing trend (73.20 ± 4.76 μm to 55.33 ± 4.16 μm) from 1 month post-onset. Multivariate analysis revealed that disease course was the primary factor influencing VF recovery (β = − 0.31, p = 0.001), while peripapillary retinal nerve fiber layer thinning was associated with gender, ethambutol dosage, and disease duration. Female patients exhibited slower peripapillary retinal nerve fiber layer thinning compared to males. This study identifies a critical recovery window for visual function in EON between 3 and 6 months, with peripapillary retinal nerve fiber layer thinning progressing significantly between 3 and 9 months. The temporal quadrant of the peripapillary retinal nerve fiber layer may serve as an early marker for disease progression. These findings provide valuable insights for optimizing monitoring and intervention strategies in EON patients, highlighting that early therapeutic interventions—particularly for patients showing temporal RNFL thinning or high-risk features—may maximize visual recovery potential.
- 22 April 2025
- Published by Wiley in European Journal of Neuroscience
- Vol. 61 (8) , e70103
Inhibition of C3/C3aR Pathway Alleviates Visual and Optic Nerve Impairments in a Rat Model of Neuromyelitis Optica Spectrum Disorder
Accumulating evidence suggests that the complement C3/C3a receptor (C3aR) pathway plays a pivotal role in the pathogenesis of neurodegenerative and autoimmune disorders, particularly neuromyelitis optica spectrum disorders (NMOSDs). Despite this, the specific pathogenic effect and mechanism of C3/C3aR pathway in NMOSD remains elusive. In this study, we demonstrated for the first time that the expression of C3aR and its upstream ligand C3 is significantly upregulated in the optic nerve of a rat model of NMOSD‐related optic neuritis (NMOSD‐ON). Our findings reveal that this upregulation leads to blood–brain barrier (BBB) disruption, demyelination and neuronal damage. Through the use of a novel C3aR inhibitor, JR14a, we demonstrate its effectiveness in reducing C3aR expression and mitigating pathological damage in the optic nerve. Furthermore, our transcriptome sequencing analysis of NMOSD optic nerve tissues reveals extensive enrichment of inflammation‐ and immune response–related pathways, with particular emphasis on the complement and coagulation cascades pathway. This study not only elucidated the crucial role of the C3‐C3aR pathway in NMOSD‐ON pathogenesis but also provided a new promising therapeutic target for NMOSD through C3aR pathway inhibition.
- 22 April 2025
- Published by Wiley in European Journal of Neuroscience
- Vol. 61 (8) , e70103
Inhibition of C3/C3aR Pathway Alleviates Visual and Optic Nerve Impairments in a Rat Model of Neuromyelitis Optica Spectrum Disorder
Accumulating evidence suggests that the complement C3/C3a receptor (C3aR) pathway plays a pivotal role in the pathogenesis of neurodegenerative and autoimmune disorders, particularly neuromyelitis optica spectrum disorders (NMOSDs). Despite this, the specific pathogenic effect and mechanism of C3/C3aR pathway in NMOSD remains elusive. In this study, we demonstrated for the first time that the expression of C3aR and its upstream ligand C3 is significantly upregulated in the optic nerve of a rat model of NMOSD‐related optic neuritis (NMOSD‐ON). Our findings reveal that this upregulation leads to blood–brain barrier (BBB) disruption, demyelination and neuronal damage. Through the use of a novel C3aR inhibitor, JR14a, we demonstrate its effectiveness in reducing C3aR expression and mitigating pathological damage in the optic nerve. Furthermore, our transcriptome sequencing analysis of NMOSD optic nerve tissues reveals extensive enrichment of inflammation‐ and immune response–related pathways, with particular emphasis on the complement and coagulation cascades pathway. This study not only elucidated the crucial role of the C3‐C3aR pathway in NMOSD‐ON pathogenesis but also provided a new promising therapeutic target for NMOSD through C3aR pathway inhibition.
- 2 April 2025
- Published by Taylor & Francis in Neuro-Ophthalmology
- Vol. 49 (3) , 218-223
Clinical Characteristics and Evolution of Ocular Manifestations in Scrub Typhus
Orientia tsutsugamushi, commonly known as scrub typhus, has long existed in the East. It falls under the category of Rickettsia infections within the Rickettsia order and the Orientia genus. It was...
- 2 April 2025
- Published by Taylor & Francis in Neuro-Ophthalmology
- Vol. 49 (3) , 218-223
Clinical Characteristics and Evolution of Ocular Manifestations in Scrub Typhus
Orientia tsutsugamushi, commonly known as scrub typhus, has long existed in the East. It falls under the category of Rickettsia infections within the Rickettsia order and the Orientia genus. It was...
- 10 March 2025
- Published by Springer Nature in Neuroscience Bulletin
- Vol. 41 (5) , 911-916
A Novel Model of Traumatic Optic Neuropathy Under Direct Vision Through the Anterior Orbital Approach in Non-human Primates
- 10 March 2025
- Published by Springer Nature in Neuroscience Bulletin
- Vol. 41 (5) , 911-916
A Novel Model of Traumatic Optic Neuropathy Under Direct Vision Through the Anterior Orbital Approach in Non-human Primates